Exelixis is an oncology-focused biopharmaceutical company best known for cabozantinib, marketed as Cabometyx and Cometriq for several cancers including kidney, liver, and thyroid disease. It builds a pipeline of small-molecule cancer therapies and partners with larger drugmakers for commercialization in some regions. Revenue is concentrated in oncology pharmaceuticals rather than broad primary-care portfolios.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 568.3 | — | 184.8 | -24.5% |
| Q3 2025 | 597.8 | — | 193.6 | 44.4% |
| Q4 2025 | 598.7 | — | 244.5 | 55.7% |
| Q1 2026 | 610.8 | — | 210.5 | 21.3% |
| Q2 2026 | 628.7 | 10.6% | 212.1 | 14.7% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Lamar Advertising Company (LAMR), Logitech International S.A. (LOGI), XP Inc. (XP), Ascendis Pharma A/S (ASND), Futu Holdings Limited (FUTU), Lattice Semiconductor Corporation (LSCC)